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Abstract
Focal Adhesion Kinase (FAK) is a non-receptor tyrosine kinase required for cell migration, proliferation and survival. FAK
overexpression has been documented in diverse human cancers and is associated with a poor clinical outcome. Recently, a
novel bis-anilino pyrimidine inhibitor, TAE226, was reported to efficiently inhibit FAK signaling, arrest tumor growth and
invasion and prolong the life of mice with glioma or ovarian tumor implants. Here we describe the crystal structures of the
FAK kinase bound to TAE226 and three related bis-anilino pyrimidine compounds. TAE226 induces a conformation of the N-
terminal portion of the kinase activation loop that is only observed in FAK, but is distinct from the conformation in both the
active and inactive states of the kinase. This conformation appears to require a glycine immediately N-terminal to the ‘‘DFG
motif’’, which adopts a helical conformation stabilized by interactions with TAE226. The presence of a glycine residue in this
position contributes to the specificity of TAE226 and related compounds for FAK. Our work highlights the fact that kinases
can access conformational space that is not necessarily utilized for their native catalytic regulation, and that such
conformations can explain and be exploited for inhibitor specificity.
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Introduction
Focal Adhesion Kinase (FAK) is a non-receptor tyrosine kinase
that regulates signals involved in cell proliferation, migration and
survival [1,2]. Following cell adhesion, FAK is recruited to focal
adhesions via its C-terminal focal adhesion targeting (FAT)
domain [3] and activated by signals from growth factor and
integrin receptors [2]. FAK activation is initiated by breaking an
intramolecular autoinhibitory interaction between the N-terminal
FERM (4.1, ezrin, radixin, moesin homology) and kinase domains
[4]. This results in rapid autophosphorylation of Tyr397 in the
linker between the FERM and kinase domains, recruitment of Src
to pTyr397 and phosphorylation of the activation loop by Src. Src
also phosphorylates tyrosines at the C-terminus of FAK, which
contains docking sites for adaptor proteins like Grb2 and Cas.
Hence, FAK exhibits dual functionality in focal adhesions as a
signaling and a scaffolding molecule.
FAK is overexpressed in many tumors including those of the
brain, ovary, colon, breast, prostate, liver and thyroid [5–10].
Furthermore, FAK overexpression is highly correlated with an
invasive phenotype in these tumors. Inhibition of FAK signaling
by overexpression of dominant-negative fragments of FAK
reduces invasion of glioblastomas [11] and ovarian cancer cells
[12]. FAK therefore represents an important target for the
development of anti-neoplastic and anti-metastatic drugs.
Several kinase inhibitors are currently in clinical use for the
treatment of cancer. Imatinib, an inhibitor of the Abl tyrosine
kinase, was the first small molecule kinase inhibitor to be approved
in the US (in 2001) and is now widely used for the treatment of
chronic myeloid leukemia. Imatinib binds to the inactive
conformation of the Abl kinase, which adopts a DFG flipped
conformation (also termed DFG-out conformation) [13,14]. The
DFG flip is characterized by a rotation of the phi backbone torsion
angle of the Asp in the DFG motif by approximately 180u. Much
of the specificity of imatinib has been attributed to its recognition
of the DFG flipped activation loop of Abl. Indeed, imatinib also
efficiently inhibits the receptor tyrosine kinase c-Kit [15,16], which
also exhibits a DFG-out conformation in its autoinhibited state
[17], whereas the much closer related Src family kinases are not
efficiently targeted [16,18]. Despite intense study, the selectivity of
imatinib for Abl over Src is still not well understood. However,
mutations in Src that were designed to destabilize the inactive Src
conformation, and therefore potentially allow Src to adopt a DFG-
out conformation with a lower energetic penalty, do exhibit
increased affinity for imatinib [18].
Recently a novel bis-anilino pyrimidine compound, TAE226,
was shown to efficiently inhibit growth and invasion of glioma and
ovarian cancer cells [19–21] and to induce apoptosis in breast
cancer cell lines [22]. Importantly, the compound efficiently
increased survival rates of animals with glioma xenografts [20] or
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3800ovarian tumor cell implants [19]. TAE226 is a potent inhibitor of
FAK (IC50=5.5 nM) and also inhibits insulin receptor (InsR) and
insulin-like growth factor-I receptor (IGF-IR), albeit ,10 fold less
potently (IC50=44 nM for InsR and IC50=140 nM for IGF-IR)
[20]. Since IGF-IR and its ligands IGF-I and IGF-II are frequently
overexpressed in gliomas [23,24], the dual specificity of TAE226
may increase its efficacy for the treatment of glioblastomas.
TAE226 displays otherwise good selectivity against a panel of 30
kinases [20].
Here we report the crystal structures of the FAK kinase in
complex with TAE226and 3 relatedbis-anilinopyrimidineanalogs.
All compounds bind to the ATP binding pocket of the FAK kinase
and the common core of the inhibitors interacts in an identical
fashion with the kinase hinge region. The structures reveal that the
carbonyl in the carbamoyl moiety of TAE226 and an analogous
carbonyl in 2 of the 3 other compounds stabilize an unusual helical
conformation of the DFG motif. This conformation is also found in
therecentlyreportedstructureofFAKincomplexwith theinhibitor
PF-562,271 [25], but differs substantially from DFG-out confor-
mations seen in other kinases. Thus, this induced conformation is
likely to confer selectivity against most kinases. Additionally, an
analogofTAE226thatfailstoinducethehelicalDFGconformation
displays a 3-fold lower potency.
Results
We solved co-crystal structures of the kinase domain of FAK in
complex with TAE226 and three other bis-anilino-pyrimidine
analogs (TAF089, TAF672 and AZW592) (Fig. 1, see Table 1 for
crystallographic parameters). In all structures, the compound
binds to the ATP binding pocket of the FAK kinase and electron
density for the compounds is well defined (see Fig. 2 for difference
electron density of TAE226). All compounds exhibit a common 5-
chloro-2-ortho-methoxyanilino-4-anilinopyrimidine core struc-
ture, which binds in a nearly identical manner to the hinge
region of the FAK kinase (Fig. 3). Two hydrogen bonds are formed
between the backbone nitrogen and carbonyl group of Cys502 of
the kinase hinge with nitrogens in the pyrimidine and 2-
methoxyaniline moieties. The carbon atoms in the pyrimidine
ring make hydrophobic contacts with Ala452 and Leu553,
whereas carbons of the 2-methoxyaniline ring interact with
Ile428 and Gly505 (Fig. 3a–d). The chlorine atom at the C5
position of the pyrimidine ring penetrates deepest into the ATP
binding pocket and is located near the gatekeeper residue Met499.
Bis-anilino pyrimidine compounds have previously been charac-
terized as inhibitors of cyclin dependent kinases (CDK2, CDK4)
[26]. Their mode of interaction with the kinase hinge region is
highly similar to that observed here.
The compounds are derivatized at both aniline rings. The
morpholine (TAE226), methylpiperazine (TAF089), dipiperidine
(TAF672) or methylaminopyrrolidine (AZW592) moieties in para
position to the amine groups of the aniline rings make almost no
protein contacts, consistent with their incorporation for improved
pharmacokinetic properties of the respective compounds. The
methyl carbamoyl moiety in ortho position to the amine in the 4-
aniline ring of TAE226 is located near the DFG motif of the
activation loop of the FAK kinase. Its carbonyl group forms a
hydrogen bond with the backbone nitrogen of Asp564 of the DFG
motif (Fig. 3a). The side chain of Leu567, the residue immediately
following the DFG sequence, makes hydrophobic contacts with
the 4-aniline ring. Interestingly, the interactions involving Asp564
and Leu567 stabilize a short helix that includes the DFG motif.
Figure 1. Schematic structures of the FAK specific inhibitors. The schematic structures of the FAK inhibitors used in this study are shown in a
consistent orientation and a conformation that is derived from their conformation when bound to FAK.
doi:10.1371/journal.pone.0003800.g001
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contacts with TAE226, is similar to the conformation induced by
the bis-amino pyrimidine FAK inhibiter PF-562,271 [25] and has
to our knowledge only been observed in FAK. In order to adopt
this helical turn the phi torsion angle of Asp564 is rotated by 113u
compared to the active kinase domain (Fig. 4a, 4b). Together, the
backbone rotations of Gly563 and Asp564 move the Ca of Asp564
by 3 A ˚ closer to the N-lobe with its side chain closely approaching
the N-lobe of the kinase.
The carbonyl within the isoindoline moieties of TAF089 and
TAF672 superimpose well with the carbonyl in TAE226 and
induce a similar helical turn at the DFG motif (Figs. 3a–c, 3e). In
contrast, AZW592, which has a sulfamoyl group at the
corresponding position, makes no significant interactions with
the activation loop, but several water molecules fill the space
between the compound and the activation loop (Fig. 3d). The
activation loop in the AZW592 bound FAK kinase follows a non-
helical path similar to the one observed in autoinhibited FAK [4].
This allows the gatekeeper residue Met499 to rotate its sidechain
towards AZW592 and it makes van der Waals contact with the
chlorine atom on the pyrimidine ring.
We evaluated the potencies of the FAK inhibitors by
determining dose-response kinase inhibition curves and deriving
IC50 values. As apparent from Table 2, TAE226 and TAF089
exhibit approximately 3-fold higher potencies than AZW592.
Inspection of the crystal structures indicates that the increased
potency may be attributed to the close contacts between the
TAE226 and TAF089 compounds with the DFGL motif in the
activation loop of FAK. IC50 values for TAF672 could not be
reliably determined because of its low solubility in DMSO and
aqueous buffers, however, it can be expected to mirror the potency
of TAF089 since the moiety that interacts with the FAK kinase is
identical for both inhibitors.
Table 1. Data collection and refinement statistics for FAK/inhibitor structures.
Compound TAE226 AZW592 TAF089 TAF672
Data collection
Space group P21 P21 P21 P21
Cell dimensions
a, b, c (A ˚) 44.1, 45.2, 67.5 44.1, 45.6, 66.4 45.7, 47.1, 63.0 44.5, 44.9, 66.4
a, b, c (u) 90, 94.7, 90 90, 95.4, 90 90, 98.6, 90 90, 95.4, 90
Resolution (A ˚)* 5 0 22.0 (2.0722.0) 5022.3 (2.3722.3) 5021.65 (1.7021.65) 5022.6 (2.6922.6)
Rmerge* 10.7 (30.8) 11.0 (24.4) 9.6 (21.1) 18.0 (29.1)
I/sI* 11.2 (2.58) 10.8 (3.36) 13.2 (3.38) 8.0 (3.08)
Completeness (%)* 93.2 (61.0) 92.6 (70.1) 94.4 (59.7) 92.1 (63.4)
Redundancy* 3.9 (2.1) 3.4 (2.6) 4.2 (1.7) 4.2 (3.0)
Refinement
Resolution (A ˚) 31.5122.0 37.5622.3 27.6721.65 33.0822.6
No. reflections 16 070 10 336 28 834 7222
Rwork/Rfree 17.9/23.6 20.8/27.2 18.8/21.7 21.5/26.2
No. atoms 2252 2194 2332 2128
Protein 2075 2084 2053 2064
Ligand 38 37 35 40
Water 139 73 244 24
Average B-factor 28.2 36.9 26.6 33.6
R.m.s deviations
Bond lengths (A ˚) 0.013 0.010 0.008 0.013
Bond angles (u) 1.400 1.475 1.168 1.295
Each dataset was collected on one single crystal.
*Highest resolution shell is shown in parentheses.
doi:10.1371/journal.pone.0003800.t001
Figure 2. Difference electron density map for the FAK/TAE226
structure. Fo-Fc electron density calculated from experimental data
and the final model with TAE226 removed is shown in stereo contoured
at 3.5 s. Positive electron density is colored green and negative density
is colored red. FAK is shown as beige ribbon with its activation loop in
cyan. TAE226 (yellow) and sidechains involved in inhibitor binding are
shown in stick representation. The ribbons of residues 429–431 in the P-
loop are rendered transparent for clarity. Difference electron density for
TAE226 is well defined.
doi:10.1371/journal.pone.0003800.g002
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Tyrosine kinases employ a remarkable variety of mechanisms in
order to achieve autoinhibition (reviewed in [27]). The structural
diversity of these inactive conformations can be an important
determinant of drug specificity. In Abl, the inactive DFG-out
conformation is exploited by the inhibitor imatinib to achieve high
specificity. It is less obvious how specificity can be achieved for
kinases like FAK that do not natively utilize unique conformations
in proximity to the active site for regulation [4]. Interestingly, the
FAK inhibitor TAE226 induces a DFG conformation in FAK that
is distinct from that observed in Abl or other kinases. The phi
torsion angle of Asp564 is rotated by approximately 110u
compared to the active FAK kinase (Figs. 4a and 4b), whereas
Figure 3. Drug binding mode of the FAK inhibitors. (a–d). The inhibitors TAE226 (a), TAF089 (b), TAF672 (c) and AZW592 (d) are shown bound
to the active site of the FAK kinase (beige ribbon with activation loop in cyan). Key side chains and the inhibitors (yellow) are shown in stick
representation. For clarity residues 429–431 in the P-loop are rendered transparent. (e) Stereoview of the superposition of the four structures
displayed in (a–d). For clarity residues 429–431 in the P-loop are removed. The substitutions at the 4-aniline ring of TAE226, TAF089 and TAF672
induce a helical conformation of the DFG motif, whereas AZW592 bound FAK exhibits an extended activation loop in this region.
doi:10.1371/journal.pone.0003800.g003
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of Abl [14], Kit [17], InsR [28], Flt3 [29], Csk [30], Raf [31] and
p38 [32], the corresponding Asp is rotated by approximately 180u
(Figs. 4c and 4d). This highlights that the conformational space
accessible to kinases is not limited to conformations used during
their native regulation cycle. The DFG/TAE226 contact in FAK
is likely to confer high potency (Table 2) and selectivity [20].
The specificity profile of TAE226 [20] suggests that the semi-
flipped conformation of the DFG motif is not accessible or not
favored in most kinases. We note that the kinases with highest
affinity for TAE226 (FAK, Pyk2, InsR, IGF-IR and ALK) all have
a glycine preceding the DFG motif. Other than these kinases, of
the 30 kinases tested by Liu et al. [20], only JAK2 and c-Raf have
a Gly at this position. Presumably, other features of these kinases
prevent potent inhibition by TAE226. Even though the Gly
preceding the DFG motif is highly conserved in FAK, it is rare
among all the tyrosine kinases in the human genome, occurring in
only 17 out of 90 tyrosine kinases [33]. It is possible that TAE226
binding and the resulting Asp564 conformation are only
energetically favored in kinases with GDFG motifs. Although in
FAK the backbone torsion angles of Gly563 fall into the additional
allowed region for non-glycine residues, it is possible that the
freedom of a glycine residue is required to accommodate the
conformational transition. Additionally, the side chain of any other
residue is likely to clash against the methyl group of the
methylcarbamoyl moiety of TAE226.
The bis-amino pyrimidine FAK inhibitor PF-562,271 was
shown to induce a DFG conformation in FAK that is very similar
to the TAE226 induced conformation [25]. Interestingly, the
selectivity profile of PF-562,271 contrasts to the one of TAE226 in
that PF-562,271 displays good selectivity against IGF-IR but
inhibits several cyclin dependent kinases relatively efficiently. It is
difficult to structurally explain these differences in specificity, but it
suggests that by combining structural features of the two inhibitors
the selectivity can be further improved.
In summary, our work highlights that in different kinases the
DFG motif and its flanking sequence exhibit variable conforma-
tional plasticity. It is emerging that compounds that are able to
lock this region into a conformation that is not favored by most
other kinases can display good specificity profiles. Imatinib is an
example of such a compound and it has successfully been
Figure 4. Partial DFG flip in TAE226 bound FAK. (a–b). The phi backbone torsion angle of D564 in TAE226 bound FAK (a) is rotated by
approximately 110u compared to FAK in the active conformation (b) (pdb accession 2j0l). This results in the side chain of D564 pointing upwards
towards the N-lobe. FAK is colored beige with its activation loop in cyan. TAE226 (a) and the DFG motif are shown in stick representation. For clarity,
residues 429–434 in the P-loop and AMP-PNP in active FAK are removed. (c–d) In Abl, D381 of the DFG motif is flipped by approximately 180u in the
imatinib bound form (c) (pdb accession 1opj) compared to the active conformation (d) (pdb accession 2g2i). Abl is colored pale yellow with its
activation loop in cyan. The ligands imatinib (c) and ADP (d) as well as residues 251–255 in the P-loop are removed because they obstruct the view of
the DFG motif.
doi:10.1371/journal.pone.0003800.g004
Table 2. IC50 values for FAK inhibitors.
Inhibitor IC50 (nM)
TAE226 6.2460.51
TAF089 7.7061.36
AZW592 17.7661.21
IC50 values were calculated by fitting the Hill slope model to inhibition curves
determined at a concentration of 10 nM purified FAK kinase and 1 mM ATP.
doi:10.1371/journal.pone.0003800.t002
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preclinical trials for the treatment of malignant gliomas [20,21]
and ovarian cancers [19]. Our work demonstrates that TAE226
locks the activation loop of FAK into a helical conformation,
which to date has only been observed in FAK and appears to
require a glycine residue immediately preceding the DFG motif.
This sequence requirement contributes to the target selectivity of
the compound, and thus to its efficacy and relatively limited
toxicity [20].
Materials and Methods
Protein expression and crystallization
The kinase domain of avian FAK (FAK411-686) was expressed
with a 6xhis-tag in insect Hifive
TM cells (Invitrogen) using the
baculovirus expression system and initially purified on Ni sepharose
beads (GE Healthcare). Subsequently, the his-tag was removed with
TEV protease and the FAK kinase was further purified by cation
exchange (MonoS, GE Healthcare) and size exclusion (Super-
dex200) chromatography. The purified protein was concentrated to
8 mg/ml in 20 mM HEPES pH 7.0, 150 mM NaCl, 5% Glycerol
and 2 mM TCEP. Inhibitor complexes were formed by incubating
the FAK kinase with 1/50 volume of aqueous inhibitor suspensions
at 100 mM for 3 h at 4uC. For crystallization, the complex was
centrifuged in a microfuge and hanging drops were set up with an
equal volume of 26% PEG4K, 200 mM LiSO4, 100 mM Tris
pH 8.5,10 mMTCEP.Crystalswere transferredintoa cryosolution
containing 8% ethylene glycol, 32% PEG4000, 200 mM LiSO4,
100 mM Tris pH 8.5, and flash-frozen.
Data collection and structure determination
Diffraction data were collected at beamline X29A at the National
Synchrotron Light Source (Brookhaven National Laboratory) and
processed with HKL2000 [34]. Phases were calculated using the
molecular replacement program PHASER [35] using the kinase
domain (pdb accession 1MP8) [36] as molecular search probe.
Refinement was performed using the program Refmac [37] and
manual rebuilding was carried out with Coot [38]. Final R-factors
were 17.9/23.6 (Rwork/Rfree) for FAK/TAE226. For a complete
summary of data collection and refinement parameters see Table 1.
Inhibition curves and IC50 value
An anti-phosphotyrosine based ELISA assay was used to
determine kinase inhibition curves. Briefly, kinase reactions were
performed with 10 nM FAK kinase (FAK411-686), 1 mM ATP,
5 mM MgCl2 and 1 mM FAK31-405 as substrate (the FAK31-405
fragment contains the Tyr397 autophosphorylation site). Inhibitor
concentrations between 0.05 and 100 nM were added and
reactions were incubated for 30 min at RT. Reactions were
stopped with 100 mM EDTA and the reaction mixtures were
transferred to 96 well Maxisorp plates (Fisher Scientific) for
immobilization. Following blocking with 5% BSA, plates were
incubated with 1:2000 PY20 antibody conjugated with HRP.
Plates were washed, developed with TMB substrate (Calbiochem)
and the absorption was monitored at 650 nm for 5 min using a
Spectra MAX Plus spectrometer (Molecular Devices). Kinase
activity was determined for each inhibitor concentration 6 times
and mean values were plotted against inhibitor concentration.
IC50 values were determined by fitting the Hill slope model to the
inhibition curves.
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